Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTH NASDAQ:ELGX NASDAQ:PAVM NASDAQ:SNWV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shsN/AELGXEndologix$0.07$0.03$0.22▼$7.10$1.41M0.731.28 million shs85,372 shsPAVMPAVmed$0.40-4.8%$0.50$0.30▼$1.90$9.21M1.09262,476 shs388,245 shsSNWVSanuwave Health$35.57-3.8%$37.94$5.63▼$46.58$316.85M1.3939,630 shs26,100 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.84%ELGXEndologix0.00%0.00%0.00%0.00%0.00%PAVMPAVmed-4.76%-6.95%-11.05%-34.58%-77.52%SNWVSanuwave Health-3.81%-0.97%-7.87%+19.00%+3,556,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.12$0.16▼$1.57$763K4.024,068 shsN/AELGXEndologix$0.07$0.03$0.22▼$7.10$1.41M0.731.28 million shs85,372 shsPAVMPAVmed$0.40-4.8%$0.50$0.30▼$1.90$9.21M1.09262,476 shs388,245 shsSNWVSanuwave Health$35.57-3.8%$37.94$5.63▼$46.58$316.85M1.3939,630 shs26,100 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.84%ELGXEndologix0.00%0.00%0.00%0.00%0.00%PAVMPAVmed-4.76%-6.95%-11.05%-34.58%-77.52%SNWVSanuwave Health-3.81%-0.97%-7.87%+19.00%+3,556,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/AELGXEndologix 0.00N/AN/AN/APAVMPAVmed 3.00Buy$19.004,648.81% UpsideSNWVSanuwave Health 3.33Buy$55.0054.62% UpsideCurrent Analyst Ratings BreakdownLatest SNWV, ARTH, PAVM, and ELGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025SNWVSanuwave HealthNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025SNWVSanuwave HealthNorthland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$55.008/22/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $55.007/29/2025SNWVSanuwave HealthRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$49.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.00N/AN/A($2.43) per share0.00ELGXEndologix$143.37M0.01N/AN/A$3.56 per share0.02PAVMPAVmed$1.02M8.60N/AN/A($0.92) per share-0.43SNWVSanuwave Health$32.63M9.34N/AN/A($1.49) per share-23.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00N/AN/A-8,257.70%N/A-730.22%N/AELGXEndologix-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/APAVMPAVmed$39.79M$1.160.34N/AN/A7,144.80%N/A-20.96%11/12/2025 (Estimated)SNWVSanuwave Health-$31.37M-$8.25N/A∞N/A-97.03%N/A-135.15%N/ALatest SNWV, ARTH, PAVM, and ELGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025SNWVSanuwave Health-$0.09$0.01+$0.10$0.01$10.14 million$10.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/AELGXEndologixN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ASNWVSanuwave HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01ELGXEndologix0.290.390.28PAVMPAVmedN/A0.520.52SNWVSanuwave HealthN/A0.430.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%ELGXEndologix51.61%PAVMPAVmed19.93%SNWVSanuwave Health42.53%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%ELGXEndologix1.30%PAVMPAVmed7.30%SNWVSanuwave Health14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableELGXEndologix52819.17 millionN/AOptionablePAVMPAVmed9021.93 million20.33 millionOptionableSNWVSanuwave Health408.57 million7.29 millionN/ASNWV, ARTH, PAVM, and ELGX HeadlinesRecent News About These CompaniesSanuwave: A Long-Term Compounder In Its Early StagesSeptember 15 at 4:06 PM | seekingalpha.comSanuwave Health (NASDAQ:SNWV) Downgraded to Buy Rating by Wall Street ZenSeptember 9, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Stock Rating Lowered by Wall Street ZenSeptember 9, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Downgraded to "Buy" Rating by Wall Street ZenSeptember 8, 2025 | americanbankingnews.comNorthland Capmk Forecasts Sanuwave Health Q3 EarningsSeptember 7, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Upgraded to "Strong-Buy" at Northland CapmkSeptember 6, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Upgraded by Northland Capmk to Strong-Buy RatingSeptember 6, 2025 | americanbankingnews.comSanuwave Health (NASDAQ:SNWV) Earns Outperform Rating from Analysts at Northland SecuritiesSeptember 6, 2025 | americanbankingnews.comNorthland Capmk Predicts Sanuwave Health Q3 EarningsSeptember 6, 2025 | americanbankingnews.comSanuwave Health (NASDAQ:SNWV) Now Covered by Northland SecuritiesSeptember 5, 2025 | marketbeat.comAWM Investment Company Inc. Invests $18.15 Million in Sanuwave Health Inc. $SNWVSeptember 5, 2025 | marketbeat.comSolas Capital Management LLC Invests $20.66 Million in Sanuwave Health Inc. $SNWVSeptember 2, 2025 | marketbeat.comSanuwave Health (NASDAQ:SNWV) Rating Increased to Strong-Buy at Wall Street ZenSeptember 1, 2025 | marketbeat.comSANUWAVE Health, Inc. (SNWV) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSanuwave (SNWV) Q2 Revenue Jumps 42%August 8, 2025 | fool.comSanuwave Announces Q2 FY2025 Financial ResultsAugust 8, 2025 | globenewswire.comSanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial ResultsAugust 4, 2025 | globenewswire.comSanuwave Health to Present at Canaccord Genuity Growth ConferenceJuly 22, 2025 | globenewswire.comSanuwave: High Growth Wound Care Tech Primed For A BreakoutJune 11, 2025 | seekingalpha.comSanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial OperationsJune 3, 2025 | globenewswire.comSANUWAVE Health, Inc. (SNWV): A Bull Case TheoryMay 29, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025SNWV, ARTH, PAVM, and ELGX Company DescriptionsArch Therapeutics OTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Endologix NASDAQ:ELGXEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.PAVmed NASDAQ:PAVM$0.40 -0.02 (-4.76%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$0.40 +0.00 (+0.22%) As of 09/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Sanuwave Health NASDAQ:SNWV$35.57 -1.41 (-3.81%) As of 09/15/2025 04:00 PM EasternSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
